10.16# Employment Agreement, dated November 23, 2018, by and between Cerevel Therapeutics, LLC and N. Anthony Coles, and amendments thereto (incorporated by reference to Exhibit 10.10 to the Current Report on Form 8-K filed by the registrant on November 2, 2020). 10.21# Employment Agreement, dated November 26, 2018, by and between Cerevel Therapeutics, LLC and Ramiro Sanchez, and amendment thereto (incorporated by reference to Exhibit 10.11 to the Current Report on Form 8-K filed by the registrant on Novemb ...

Company Participants Susan Altschuller - Chief Financial Officer Jeff Hung - Morgan Stanley Good morning and welcome to the Cerevel Therapeutics Third Quarter Financial Results Conference call. At this time, all participants are in listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded. I will now hand the call over to Ron Renaud, President and CEO of Cerevel, to provide an overview of our achievements and outloo ...

Forward-Looking Statements Cerevel: Becoming the premier neuroscience company • Raised $499 million net proceeds from public offering of common stock in October 2023 © Cerevel Therapeutics Holdings, Inc. 2 Forward-looking statements in this presentation include, but are not limited to, statements about: the potential attributes and benefits of our product candidates; the format, timing and objectives of our product development activities and clinical trials; the timing and outcome of regulatory interactions ...

Additional laws and regulations governing international operations could negatively impact or restrict our operations. 72 We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations. Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade Laws, pr ...

Matthew Calistri - Vice President of Investor Relations John Renger - Chief Scientific Officer Michael DiFiore - Evercore ISI Tazeen Ahmad - Bank of America Jeff Hung - Morgan Stanley Douglas Tsao - H.C. Wainwright Matthew Calistri Company Participants Raymond Sanchez - Chief Medical Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Good morning and welcome to Cerevel Therapeutics Second Quarter Financial Results Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39311 CEREVEL THERAPEUTICS HOLDINGS, INC. (Exact name of Registrant as specified in its Char ...

© Cerevel Therapeutics Holdings, Inc. 1 Cerevel: Becoming the premier neuroscience company © Cerevel Therapeutics Holdings, Inc. 4 Unraveling the Mysteries of the Brain to Treat Neuroscience Diseases May 2023 1Q 2023 Financial Results & Business Update Forward-Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the fol ...

Interest Income (Expense), Net | --- | --- | --- | --- | --- | |-----------------------------------------------------|-------|-----------------------|-------|---------------------| | ASSETS | | As \nMarch 31, 2023 | of | December 31, 2022 | | Current assets: | | | | | | Cash and cash equivalents | $ | 153,816 | $ | 136,521 | | Marketable securities | | 673,171 | | 755,509 | | Prepaid expenses and other current assets | | 13,795 | | 13,621 | | Total current assets | | 840,782 | | 905,651 | | Marketable secur ...

PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 113 Item 6. Reserved 114 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 114 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 129 Item 8. Financial Statements and Supplementary Data 129 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 129 Item 9A. Controls and Procedures 130 It ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39311 CEREVEL THERAPEUTICS HOLDINGS, INC. (Exact Name of Regist ...